Kemp Dolliver
Stock Analyst at Brookline Capital
(0)
# 4610
Out of 5,218 analysts
24
Total ratings
25.00%
Success rate
-16.23%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Y-mAbs Therapeutics | Initiates Coverage On: Buy | 17 | 9.37 | 81.43% | 1 | Dec 5, 2024 | |
Eyenovia | Downgrades: Hold | n/a | n/a | n/a | 2 | Nov 15, 2024 | |
Verrica Pharmaceutic... | Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 2, 2024 | |
Oncternal Therapeuti... | Downgrades: Hold | n/a | n/a | n/a | 3 | Sep 12, 2024 | |
iBio | Initiates Coverage On: Buy | 4 | 2.31 | 55.84% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 | 3.18 | 1032.08% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 32 | 1.48 | 2021.62% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 27 13 | n/a | n/a | 1 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 93.11 | 7.4% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 57 | 1.94 | 2838.14% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 | 2.43 | 85.19% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 25 | 2.33 | 972.96% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 19 | 13.72 | 36.66% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 8 | 1.14 | 601.75% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.06 | 433.02% | 1 | Feb 2, 2022 |